안트로젠

065660KOSDAQ기타 전문 도매업

51.0 / 100

Reference Date: 2026-07-24

Financial Score17.0 / 40

News Sentiment20.0 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 16.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Antrogen is a biotech company specializing in the development and production of stem cell-based therapeutics, having commercialized the world's first adipose-derived stem cell treatment for Crohn's disease fistulas, 'Cupistem,' in 2012. It also holds exclusive distribution rights for pulmonary hypertension treatments 'Remodulin' and 'Tyvaso' in South Korea, while expanding its pipeline for tissue-engineered therapies and treatments for rare/incurable diseases.

Number of Employees

32people

Average Salary

34.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 12.754.0Point

PBR

1.98Industry Average 0.580.0Point

3.4x industry avg (risky)

ROE

-1.39Industry Average 2.090.0Point

Well below industry avg

Debt Ratio

0.22Industry Average 7.878.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲7.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲30.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -1.9% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 3Neutral 0Negative 1Average Sentiment Score 80

Positive
김미형 안트로젠 대표 “日 알로스템시트 잠재 환자 1000명 이상”
안트로젠의 일본 알로스템시트 치료제가 보험약가 등재를 앞두고 잠재 환자 수가 1000명 이상으로 예상되어 긍정적인 시장 반응을 기대.
Positive
[만나보니] 안트로젠 "국산 줄기세포 치료제 수출 시대 열었다"
안트로젠의 줄기세포 치료제 '알로스템' 일본 첫 수출로 글로벌 시장 진출 성공.
Positive
안트로젠, 日 허가 발판삼아 美 임상 2상 추진…알로스템 글로벌 개발....
안트로젠의 주요 치료제 알로스템이 일본에서 품목허가를 받음으로써 미국 임상 2상 및 글로벌 확장 계획이 가속화되어 긍정적인 시장 반응을 기대할 수 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 17,290Won52-week high 58,00052-week low 15,030

1-month return0.0Point

1m -16.27% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-09